Author
Institute of Medical Science, The University of Tokyo
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
10 papers
Recent·Most cited
Amin Addetia, Keiya Uriu, Cameron Stewart, Kaitlin R. Sprouse, Yu Kaku, Mohammad Golam Kibria, Olivia Putri, SM Tanjil Shah, Yuri Fukushima, Shushuke Kawakubo, Young-Jun Park, Akatsuki Saito, Kei Sato, David Veesler
This study determines the structure of the 2026 Bundibugyo virus glycoprotein and identifies conserved epitopes for antibody therapeutics and pan-ebolavirus vaccines.
bioRxiv · Oct 23, 2026 · PreprintBiochemistry
Kaoru Usui, Masumi Tsuda, Keiya Uriu, Shigeru Fujita, Yukie Kashima, Yutaka Suzuki, Lei Wang, Shinya Tanaka, Jumpei Ito, Kei Sato
This study experimentally infects horseshoe bats with SARS-CoV-2, showing low-level persistent viral replication without disease, and identifies host mechanisms that enable viral coexistence.
bioRxiv · Mar 25, 2026 · PreprintMicrobiology
Keiya Uriu, Yu Kaku, Yusuke Kosugi, Luo Chen, Naoya Itoh, Yoshifumi Uwamino, Hiroshi Fujiwara, Hironori Satoh, Kei Sato
This study evaluates the neutralizing antibody response induced by XEC-based monovalent vaccines against multiple SARS-CoV-2 variants, showing enhanced immunity against JN.1 subvariants compared to other variants.
Vaccine · Feb 10, 2026Peer-reviewedMicrobiology
Shuhei Tsujino, Masumi Tsuda, Sayaka Deguchi, Jumpei Ito, Taha Y. Taha, Hesham Nasser, Lei Wang, Julia Rosecrans, Rigel Suzuki, Saori Suzuki, Kumiko Yoshimatsu, Mélanie Ott, Terumasa Ikeda, Kei Sato, Kazuo Takayama, , Miki Kawano
This study identifies the non-spike R204P mutation in the SARS-CoV-2 Omicron XEC variant as a driver of increased inflammation and pathogenicity through NF-κB activation.
Nature Communications · Dec 14, 2025Peer-reviewedMicrobiology
Yu Kaku, Mizuka Fujiwara, Keiya Uriu, Maximilian Stanley Yo, Shusuke Kawakubo, Jumpei Ito, Naoya Itoh, Yoshifumi Uwamino, Fumitake Saito, Hironori Satoh, Kei Sato
This study evaluates the humoral immune response induced by LP.8.1-based vaccines against multiple SARS-CoV-2 variants, showing effective cross-neutralization and immune boosting.
bioRxiv · Nov 18, 2025 · PreprintMicrobiology
Keiya Uriu, Yu Kaku, Yoshifumi Uwamino, Hiroshi Fujiwara, Fumitake Saito, Kei Sato
This study compares the antiviral humoral immunity induced by two JN.1 monovalent mRNA vaccines against multiple SARS-CoV-2 Omicron subvariants and XEC, showing both vaccines boost immunity with statistical significance.
The Lancet Infectious Diseases · Dec 10, 2024Peer-reviewedMicrobiology
Yu Kaku, Kaho Okumura, Shusuke Kawakubo, Keiya Uriu, Chen Luo, Yusuke Kosugi, Yoshifumi Uwamino, MST Monira Begum, Sharee Leong, Terumasa Ikeda, Kenji Sadamasu, Hiroyuki Asakura, Mami Nagashima, Kazuhisa Yoshimura, Jumpei Ito, Kei Sato
This study analyzes the virological characteristics of the SARS-CoV-2 XEC variant, showing it has higher infectivity and immune evasion compared to KP.3.1.1, contributing to its higher reproductive number and potential dominance.
The Lancet Infectious Diseases · Nov 6, 2024Peer-reviewedMicrobiology
Yu Kaku, Keiya Uriu, Kaho Okumura, Jumpei Ito, Kei Sato
This paper investigates the virological properties of the SARS-CoV-2 KP.3.1.1 variant, finding it has higher transmissibility and immune evasion compared to KP.3.
The Lancet Infectious Diseases · Aug 16, 2024Peer-reviewedMicrobiology
Yu Kaku, Maximilian Stanley Yo, Jarel Elgin Tolentino, Keiya Uriu, Kaho Okumura, Jumpei Ito, Kei Sato
This study evaluates the virological properties of SARS-CoV-2 variants KP.3, LB.1, and KP.2.3, finding higher reproduction numbers and immune evasion compared to JN.1.
The Lancet Infectious Diseases · Jun 27, 2024Peer-reviewedMicrobiology
Yu Kaku, Keiya Uriu, Yusuke Kosugi, Kaho Okumura, Daichi Yamasoba, Yoshifumi Uwamino, Jin Kuramochi, Kenji Sadamasu, Kazuhisa Yoshimura, Hiroyuki Asakura, Mami Nagashima, Jumpei Ito, Kei Sato
This study investigates the virological properties of the SARS-CoV-2 KP.2 variant, finding it has higher viral fitness and immune resistance compared to JN.1, contributing to its rapid spread.
The Lancet Infectious Diseases · May 20, 2024Peer-reviewedMicrobiology